The prevalence and burden of Rome IV bowel disorders of gut brain interaction in patients with non-alcoholic fatty liver disease: a cross-sectional study.
Huw Purssell, Lucy Bennett, Oliver Street...
https://pubmed.ncbi.nlm.nih.gov/37253969/Actively Recruiting
Led by Buddhist Tzu Chi General Hospital · Updated on 2026-10-05
45
Participants Needed
1
Research Sites
N/A
Total Duration
Functional dyspepsia FD involves inflammatory responses triggered by histamine release from eosinophils and mast cells, leading to increased intestinal mucosal permeability. This permeability is a key factor in FD development. Researchers are exploring the effects of combining H1 and H2 antihistamine antagonists compared to using only H1 antagonists, as current evidence shows both types can be effective but have not been directly compared. The study also considers the overlap of fatty liver disease and irritable bowel syndrome IBS which share common factors and may worsen symptoms and quality of life. Participants are divided into groups to receive different treatments one group takes famotidine an H2 antagonist plus levocetirizine an H1 antagonist, another group takes only levocetirizine, and a control group receives placebo. Medications are given at specified doses and times, such as famotidine 20mg twice daily and levocetirizine 5mg once before bed. Some groups also receive Fuyuan Gasmin tablets to help reduce gastrointestinal gas. This phase 2 randomized trial runs for 84 days, assessing the impact of these therapies on symptoms and underlying physiological changes. During the study, participants undergo evaluations at baseline and day 84, which include symptom scales for functional dyspepsia, gastrointestinal pain, sleep quality, depression, anxiety, stress, and visceral sensitivity. Researchers monitor changes in these scores to assess treatment effects. Participants are monitored for adherence and safety throughout the trial. The total study duration is about 12 weeks, with regular assessments to track progress and any side effects.
CONDITIONS
Exploring Novel Therapeutic Approaches for Disorders of Gut-Liver-Brain Interaction-H1/H2
M
Ming-Wun Wong
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Buddhist Tzu Chi General Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 84 days
Participants receive either a combination of famotidine and levocetirizine, levocetirizine alone, or a placebo according to a randomized assignment.
Visits at baseline and day 84
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Huw Purssell, Lucy Bennett, Oliver Street...
https://pubmed.ncbi.nlm.nih.gov/37253969/Xiao-Yuan Mao, Xi-Xi Yin, Qi-Wen Guan...
https://pubmed.ncbi.nlm.nih.gov/33901506/Vincent Wai-Sun Wong, Julien Vergniol, Grace Lai-Hung Wong...
https://pubmed.ncbi.nlm.nih.gov/20101745/Niv Zmora, Jotham Suez, Eran Elinav
https://pubmed.ncbi.nlm.nih.gov/30262901/Bruno Bonaz, Valérie Sinniger, Sonia Pellissier
https://pubmed.ncbi.nlm.nih.gov/30201788/Ai Huey Tan, Shen Yang Lim, Anthony E Lang
https://pubmed.ncbi.nlm.nih.gov/35750883/Rena Yadlapati, C Prakash Gyawali, John E Pandolfino...
https://pubmed.ncbi.nlm.nih.gov/35123084/N Montano, C Cogliati, A Porta...
https://pubmed.ncbi.nlm.nih.gov/9760293/Xin Dai, Bangmao Wang
https://pubmed.ncbi.nlm.nih.gov/25945084/T Tyler Patterson, Susannah Nicholson, David Wallace...
https://pubmed.ncbi.nlm.nih.gov/30335675/Buddhist Tzu Chi General Hospital
Lead Sponsor